2022-04-01
Cellaviva delivers stem cells to treat serious blood disease
NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.
Read moreRead more2022-02-22
The Canadian ProTrans in COVID-19 single center trial is expanded to a multicenter trial
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada. The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill University Health Center. Patient enrolment increased due to the omicron variant, which we envisage will be further enhanced by patient reqruitment at both sites, the Royal Victoria and Jewish General Hospital.
The coronavirus pandemic has transformed over time and omicron has shown to be more
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada. The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill U...
Read moreRead more2022-02-21
Pediatric diabetes study with ProTrans in progress
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon undergo treatment.
The first part of the study is a safety part (phase Ib) where all patients are treated at Akademiska university hospital. 3 patients aged 12-18 years receive treatment first and there after 3 patients aged 7-11 years. The data will then be reviewed by the Data Safety Monitoring Board,
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon und...
Read moreRead more2022-02-18
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy where the replay and the presentations will be available afterwards.
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medici...
Read moreRead more2022-02-08
NextCell invests in CAR-T technology
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, whereas its ownership in FamiCordTx will change from 9,43% to 8,45% of the then shares.
FamiCordTx S.A., raised PLN 16 million (approximatly MEUR 3,5) from a pre-IPO issue of shares
• The proceeds from the issue will be used to fund the Phase 1 clinical trials of CAR T (chimeric antigen receptor
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, ...
Read moreRead more2022-01-27
NextCell Pharma publishes Interim Report 1 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
First quarter (2021-09-01 until 2021-11-30)
● Operating income amounted to TSEK 1 347 (1 148).
● Operating result amounted to TSEK -6 472 (-5 473).
● Earnings per share* amounted to
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth ...
Read moreRead more2022-01-25
NextCell invited speaker at the prestigious Advanced Therapy Week in USA
NextCell Pharma AB ("NextCell" or the"Company") has been invited to give a presentation about the company journey within the cell therapy arena. Starting as a Karolinska Institute spin-out to phase II clinical trials listed on Nasdaq.
The Miami-based meeting is the largest event in the Cell & Gene Therapy arena and brings together a range of key opinion leaders in the advanced therapies field with an expected 1650 participants. The wider theme for the meeting is to advocate for the application of advanced therapies in healthcare, by innovation & investment, manufacturing, logistics and
NextCell Pharma AB ("NextCell" or the"Company") has been invited to give a presentation about the company journey within the cell therapy arena. Starting as a Karolinska Institute spin-out to phase II clinical trials listed on Nasdaq.
The Miami-based meeting is the largest event in the Cell & Ge...
Read moreRead more2021-12-13
NextCell collaborates with T.A.D.1 and T1D app
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. Together, we want to spread hope for type 1 diabetes and make NextCell's clinical trials visible.
Every year, more than 900 children are diagnosed with type 1 diabetes and at least as many are diagnosed in adulthood. The disease has a huge impact on life and something that needs to be dealt with daily, for the rest of your life.
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. Together, we want to spread h...
Read moreRead more